.
2065 Background: Glioblastoma (GBM) contains extensive hypoxic regions due to tumor-associated thrombosis and abnormal vasculature. Hypoxia drives resistance to radiation (RT) and temozolomide (TMZ) by limiting oxygen-dependent DNA damage, enabling DNA repair, and reducing drug efficacy and delivery. The RESTORE trial (NCT03862430) is the first randomized, prospective, placebo-controlled study of NanO₂ (2% w/v dodecafluoropentane emulsion) in GBM, a fluorocarbon-based oxygen therapeutic hypothesized to reoxygenate hypoxic GBM tissue, with the goal of enhancing the efficacy of chemoradiation. Methods: Patients with newly diagnosed GBM (WHO 2021) received standard-of-care radiation (60 Gy) with concurrent TMZ (75 mg/m²/day). Patients were randomized 2:1 to receive either NanO 2 or 0.9% sodium chloride administered intravenously immediately prior to each RT fraction, with continuous supplemental oxygen given during the infusion and RT. Following chemoradiation, patients completed a four-week recovery period before initiating adjuvant TMZ for 6 cycles. The primary endpoint is progression free survival and secondary endpoints include overall survival, objective response rate, pseudoprogression rate, and patient reported outcomes. Results: Between May 2023 and October 2025, 93 patients were treated (safety set). The study has completed the planned enrollment. Median age was 63 years (range, 19–84) and 57% were men. As of the data cutoff on 12/29/25, all patients completed the follow up visit 4 weeks after chemoradiation. Sixty-eight patients (73%) remained on study undergoing adjuvant TMZ or in long-term follow-up. Twenty-one patients passed of tumor progression and 4 patients withdrew consent. The median duration on study was 8.7 months (range, 1.3–31.4). During chemoradiation and the four-week recovery, 63 treatment-emergent adverse events (TEAEs) of CTCAE severity grade ≥3 were reported in 37% of patients, with brain edema, lymphocyte count decreased, and platelet count decreased being the most frequently reported. Twenty-six treatment-emergent serious adverse events (TESAEs) occurred in 19% of patients, with embolism, pulmonary embolism, and seizure being the most frequently reported. Three TESAEs were assessed as possibly or probably related to study drug; none were unexpected. Survival follow up is ongoing. Conclusions: In this blinded, pooled safety analysis of a randomized phase 2 trial in newly diagnosed GBM, the study treatment was well tolerated and no new safety signals were identified. Treatment allocation remains blinded. Efficacy outcomes and arm-specific safety analyses will be reported after completion of the primary endpoint analysis. Clinical trial information: NCT03862430 .
Despite over 13 billion SARS-CoV-2 vaccine doses administered globally, persistent post-vaccination symptoms, termed post-COVID-19 vaccine syndrome (PCVS), resemble post-acute sequelae of COVID-19 (PASC). Symptoms like cardiac, vascular, and neurological issues often emerge shortly after vaccination and persist for months to years, mirroring PASC. We previously showed the S1 subunit of the SARS-CoV-2 spike protein persists in CD16+ monocytes after infection, potentially driving PASC. Approved vaccines (Pfizer, Moderna, Janssen, AstraZeneca) deliver synthetic S1 to elicit immunity, suggesting a shared mechanism. We hypothesized that vaccine-derived S1 persistence in CD16+ monocytes sustains inflammation akin to PASC, contributing to PCVS. We studied 50 individuals with PCVS symptoms lasting over 30 days post-vaccination and 26 asymptomatic controls, using (1) machine learning-based immune profiling to compare cytokine signatures with PASC, (2) flow cytometry to detect S1 in CD16+ monocytes, and (3) LC-MS to confirm S1 across vaccine types. We correlated S1 persistence with symptom duration and inflammation. Prior infection was excluded via clinical history, anti-nucleocapsid antibody tests, and T-detect assays, though definitive tests are lacking. Preliminary findings suggest S1 persistence in CD16+ monocytes and an associated inflammatory profile may contribute to PCVS. Further studies are needed to confirm causality and prevalence.
There is a major unmet need in emergency departments for diagnostics that aid in rapid sepsis risk assessment of potentially infected patients [1-3]. In this study, we evaluated the results of implementation of a novel host response test (HR) as part of the protocolized screening and guideline-directed treatment pathway process for patients at risk of sepsis, in four geographically distinct EDs within a health system. The HR test, which generates an Index based on the state of immune activation stratified into 3 interpretation bands (Band 1- 3) of increasing sepsis likelihood [4], was integrated into the protocolized response to suspected infection at four EDs in Baton Rouge, LA (S1, 9/24/2024 :1/24/2025), Lafayette, LA (S2, 9/24/2024 :1/24/2025), (Jackson, MS (S3, 8/27:12/27/2024) and Monroe, LA (S4, 8/27: 12/27/2024). At all sites, screening and ordering was achieved through 2 mechanisms, a triage-based nurse-driven protocol, and a later physician-driven protocol. Guideline-directed treatment pathways based on the results of the HR test were adopted by the health system. Patients with missing data for discharge disposition were omitted from this analysis. ED returns were ruled as those who had an ED encounter within 30 days of their original encounter, excluding encounters with discharge ICD-10 diagnosis codes related to mental health (F1-99), substance abuse (F10-19), chronic pain (G89), sickle cell disease (D57), end of life care (Z51.5), injury/poisoning (S1-99,T1-88), or external morbidity (V1-99, Y1-99). Return-adjusted hospital free days was calculated by further subtracting a patient’s length of stay for ed returns within 30 days from the original encounter, or by setting it to zero for mortalities on such returns. This study consisted of 4650 patients with 758, 764, 1930, and 1198 from sites 1-4, respectively. Of these 2546 (54.8%), 1194 (25.7%), and 910 (19.6%) returned HR results of Bands 1-3, respectively. From month 1 (M1) to month 4 (M4), a 12.3% and 8.2% increase in rates of ED discharge was observed in Band 1 (M1 22.0%, M4 34.3%, p < 0.01) and Band 2 (M1 10.5%, M4 18.7%, p < 0.05, Fig1A), respectively. During this period, no significant change to rates of ED return was observed across any Band. Additionally, an overall 1 day increase in median return-adjusted hospital free days was observed across the entire cohort from M1 to M4 (M1 26.0, M4 27.0, p < 10-4), with a significant 1-day increase (M1 27.0, M4 28.0, p < 10-4) and 2-day increase (M1 25.0, M4 27.0, p < 0.05, Fig1B) in Bands 1-2, respectively. These findings suggest that the addition of a host response test as an aid in risk stratification to protocolized screening and treatment of those presenting to the ED suspected of infection may lead to improved rates of ED discharge and hospital-free days in geographically diverse EDs.